Skip to main content
. 2021 Sep 30;3(6):100380. doi: 10.1016/j.jhepr.2021.100380

Table 4.

Differences in LI-RADS-defined TIV, LR-M features, and major features in NOS-HCC, SH-HCC, and MTM-HCC subtypes in the entire cohort with contrast-enhanced MRI (n = 227).

Features NOS-HCC
(n = 165)
SH-HCC
(n = 48)
MTM-HCC
(n = 14)
p value R1 vs. R2
N agreement (%)
κ value (95% CI)
R1 vs. R3
N agreement (%)
κ value (95% CI)
R2 vs. R3
N agreement (%)
κ value (95% CI)
TIV
 R1 7 (4.2) 0 (0) 2 (14.3) 0.052 219 (96.5) 225 (99.1) 219 (96.5)
 R2 11 (6.7) 0 (0) 4 (28.6) 0.001 0.64 (0.42, 0.87) 0.88 (0.72, 1.00) 0.64 (0.42, 0.87)
 R3 7 (4.2) 0 (0) 2 (14.3) 0.052

LR-M features

At least 1 LR-M feature
 R1 65 (39.4) 10 (20.8) 6 (42.9) 0.052 177 (78.0) 182 (80.2) 184 (83.7)
 R2 66 (40.0) 11 (22.9) 4 (28.6) 0.080 0.52 (0.40, 0.63) 0.55 (0.43, 0.66) 0.57 (0.45, 0.68)
 R3 51 (30.9) 11 (22.9) 6 (42.9) 0.314
At least 1 targetoid feature
 R1 14 (8.5) 3 (6.2) 2 (14.3) 0.630 208 (91.6) 205 (90.3) 208 (91.6)
 R2 12 (7.3) 4 (8.3) 0 (0) 0.550 0.41 (0.19, 0.62) 0.39 (0.19, 0.60) 0.44 (0.23, 0.65)
 R3 15 (9.1) 4 (8.3) 2 (14.3) 0.788
Rim APHE
 R1 8 (4.8) 3 (6.2) 2 (14.3) 0.212 214 (94.3) 212 (93.4) 211 (93.0)
 R2 6 (3.6) 2 (4.2) 0 (0) 0.750 0.35 (0.08, 0.62) 0.44 (0.21, 0.68) 0.30 (0.05, 0.54)
 R3 13 (7.9) 1 (2.1) 2 (14.3) 0.365
Peripheral ‘washout’
 R1 0 (0) 1 (2.1) 0 (0) 0.154 226 (99.6) 223 (98.2) 224 (98.7)
 R2 0 (0) 0 (0) 0 (0) 1.000 0.00 (0.000, 0.00) −0.006 (−0.01, 0.003) 0.00 (0.000, 0.00)
 R3 3 (1.8) 0 (0) 0 (0) 0.565
Delayed central enhancement
 R1 6 (3.6) 0 (0) 0 (0) 0.314 219 (96.5) 222 (97.8) 218 (96.0)
 R2 5 (3.0) 1 (2.1) 0 (0) 0.765 0.31 (−0.03, 0.66) 0.53 (0.17, 0.89) 0.16 (−0.15, 0.47)
 R3 4 (2.4) 1 (2.1) 0 (0) 0.837
Targetoid restriction
 R1 1 (0.6) 1 (2.2) 0 (0) 0.589 215 (99.1) 210 (96.8) 212 (97.7)
 R2 1 (0.6) 1 (2.2) 0 (0) 0.079 0.49 (−0.10, 1.00) −0.01 (−0.02, 0.0003) 0.27 (−0.16, 0.71)
 R3 3 (1.9) 2 (4.3) 0 (0) 0.524
Targetoid appearance on HBP
 R1 (adequate, n = 59) 1 (2.3) 0 (0) 0 (0) 0.828 38 (97.4) 38 (97.4) 39 (100)
 R2 (adequate, n = 53) 1 (2.6) 0 (0) 0 (0) 0.818 0.00 (0.000, 0.00) 0.00 (0.000, 0.00) 0.00 (0.000, 0.00)
 R3 (adequate, n = 55) 0 (0) 0 (0) 0 (0) 1.000
Infiltrative appearance
 R1 12 (7.3) 0 (0) 2 (14.3) 0.078 219 (96.5) 219 (96.5) 221 (97.3)
 R2 10 (6.1) 0 (0) 2 (14.3) 0.076 0.67 (0.46, 0.88) 0.64 (0.42, 0.87) 0.71 (0.49, 0.83)
 R3 10 (6.1) 0 (0) 0 (0) 0.140
Marked restricted diffusion
 R1 5 (3.2) 0 (0) 2 (14.3) 0.301 202 (93.1) 201 (92.6) 198 (91.3)
 R2 10 (6.4) 0 (0) 2 (14.3) 0.084 0.17 (−0.07, 0.42) 0.19 (−0.03, 0.42) 0.16 (−0.07, 0.40)
 R3 11 (7.0) 0 (0) 2 (14.3) 0.085
Necrosis or severe ischaemia
 R1 45 (27.3) 8 (16.7) 3 (21.4) 0.311 193 (85.0) 196 (86.4) 198 (87.2)
 R2 41 (24.8) 8 (14.5) 3 (21.4) 0.490 0.58 (0.46, 0.71) 0.58 (0.45, 0.71) 0.59 (0.46, 0.72)
 R3 27 (16.4) 7 (14.6) 3 (21.4) 0.829

Major features

Size (mm)
 R1 44.0 (27.0, 64.5) 30.0 (19.0, 46.7) 59.5 (26.0, 100.5) 0.007 0.98 (0.97, 0.98) 0.98 (0.97, 0.98) 0.98 (0.97, 0.98)
 R2 46.0 (31.0, 70.0) 35.0 (23.2, 54.7) 67.5 (34.0, 130.0) 0.007
 R3 44.0 (27.0, 71.5) 30.0 (22.0, 50.2) 61.0 (23.7, 114.7) 0.011
Non-rim APHE
 R1 144 (87.3) 44 (91.7) 11 (78.6) 0.406 202 (89.0) 203 (89.4) 188 (82.9)
 R2 153 (92.7) 45 (93.8) 14 (100) 0.572 0.36 (0.51, 0.55) 0.59 (0.45, 0.74) 0.24 (0.08, 0.39)
 R3 133 (80.6) 42 (87.5) 10 (71.4) 0.337
Non-peripheral ‘washout’
 R1 145 (87.9) 37 (77.1) 14 (100) 0.049 202 (89.0) 198 (87.2) 191 (84.2)
 R2 144 (87.3) 39 (81.2) 14 (100) 0.178 0.52 (0.36, 0.68) 0.54 (0.39, 0.68) 0.43 (0.26, 0.57)
 R3 131 (79.4) 39 (81.2) 13 (92.9) 0.469
Enhancing ‘capsule’
 R1 117 (70.9) 32 (66.7) 11 (78.6) 0.673 187 (82.4) 185 (81.5) 177 (77.9)
 R2 120 (72.7) 30 (65.5) 10 (71.4) 0.391 0.57 (0.46, 0.69) 0.53 (0.41, 0.66) 0.45 (0.23, 0.58)
 R3 124 (75.2) 32 (66.7) 12 (85.7) 0.293
Threshold growth
 R1 2 (1.2) 0 (0) 0 (0) 0.684 223 (98.2) 221 (97.3) 221 (97.3)
 R2 1 (0.6) 0 (0) 1 (7.1) 0.032 −0.008 (−0.01, −0.0001) 0.24 (−0.15, 0.63) 0.24 (−0.15, 0.63)
 R3 3 (1.8) 1 (2.1) 2 (14.3) 0.020

Categorical variables are expressed as numbers and percentages in parentheses. The continuous variable (size) is reported as median and IQR (25th to 75th percentiles) in parentheses. Differences between HCC subtypes were assessed using the Pearson χ2 test for categorical variables. Inter-reader agreement was assessed using the Cohen’s kappa (κ) test for categorical variables and intraclass correlation coefficient of the continuous variable (size). Statistically significant values (p <0.05) are highlighted in bold.

APHE, arterial phase hyperenhancement; HBP, hepatobiliary phase; LI-RADS, Liver Imaging Reporting and Data System; MRI, magnetic resonance imaging; MTM-HCC, macrotrabecular massive hepatocellular carcinoma; NOS-HCC, not otherwise specified hepatocellular carcinoma; R1, Reader 1; R2, Reader 2; R3, Reader 3; SH-HCC, steatohepatitic hepatocellular carcinoma; TIV, tumour-in-vein.

Features assessed in 217/227 observations as a result of the lack of diffusion weighted imaging in 10 observations.

Agreement assessed only in observations considered with adequate HBP for all readers.

Agreement assessed with intraclass correlation coefficient.